P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Nurse loses leg after cutting foot, contracting bacterial infection while on Florida vacation SURPRISE, Ariz. ( KPHO /Gray News) – A nurse in Arizona is adjusting to his new normal after losing his ...

In the realm of orthopedic medicine, the challenge of managing infected bone defects (IBDs) has persisted as a significant ...